3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Conditions
Ovarian Neoplasms
8
Uterine Cervical Neoplasms
5
Melanoma
5
Head and Neck Neoplasms
5
Urinary Bladder Neoplasms
4
Triple Negative Breast Neoplasms
4
Stomach Neoplasms
4
Neoplasms
4
Fallopian Tube Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Endometrial Neoplasms
3
Prostatic Neoplasms
2
Kidney Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Merkel Cell
2
Carcinoma, Hepatocellular
2
Vulvar Neoplasms
1
Uveal Melanoma
1
Uterine Neoplasms
1
Thyroid Neoplasms
1
Skin Neoplasms
1
Sarcoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Interventions
pembrolizumab
5
Cyclophosphamide
4
Carboplatin
4
Filgrastim
3
fludarabine
2
Thiotepa
2
Temozolomide
2
Riluzole
2
Psychiatric Rehabilitation
2
Polymerase Chain Reaction
2
Peripheral Blood Stem Cell Transplantation
2
Immunohistochemistry
2
Drug Therapy
2
Counseling
2
Bupropion
2
vofatamab
1
utomilumab
1
trastuzumab deruxtecan
1
toripalimab
1
tasquinimod
1
sodium thiosulfate
1
sargramostim
1
saracatinib
1
poly ICLC
1
pertuzumab
1
liposomal doxorubicin
1
lenvatinib
1
ixabepilone
1
etoposide phosphate
1
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liver Neoplasms
×
cemiplimab
×
Gynecologic
×
Clear all
NCT06923761
2026-01-28
EMITT-1
Grey Wolf Therapeutics
Phase 1/2
Recruiting
300 enrolled